SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is facing significant volatility and intense community debate after announcing a massive equity offering to fund a large backlog of AI server orders. While some investors view the dilution as a necessary step to capitalize on strong demand, others are expressing frustration over the timing and the company's long-standing governance concerns.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors debate the impact of upcoming DEA rescheduling hearings against the company's aggressive pivot toward an alcohol-focused strategy. Community sentiment remains deeply divided, with some highlighting the stock's potential for global market expansion and others expressing frustration over persistent dilution and the company's lack of immediate U.S. plant-touching cannabis operations.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is facing intense selling pressure as a strengthening USD, surging treasury yields, and broader market volatility drive investors to liquidate precious metals positions. The community remains deeply divided, with some investors aggressively accumulating physical silver as a long-term hedge against potential inflation, while others view the recent price drop as evidence that silver has failed as a reliable store of value.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong investor interest driven by positive Phase 1 data for its subcutaneous BRIUMVI treatment in Myasthenia Gravis and ongoing speculation regarding a potential buyout. The community is actively discussing the company's expanding addressable market, potential acquisition targets, and the strategic positioning of its product pipeline against competitors.

Cracker Barrel Old Country Store, Inc. engages in the operation and development of restaurant and retail outlets. The format of its stores consists of a trademarked rustic old country-store design that offers restaurant menu featuring home-style country food. The company was founded by Dan W. Evins on September 19, 1969 and is headquartered in Lebanon, TN.

Cracker Barrel Old Country Store Inc

Cracker Barrel is seeing significant volatility as market participants debate its turnaround potential following a stronger-than-expected earnings beat and raised guidance. Investors are actively discussing the company's efforts to address declining traffic and margin pressures, with the high level of short interest fueling speculation about a potential squeeze while some remain skeptical of long-term stability.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

The DJT stock is currently at the center of heated online debate, fueled by ongoing community scrutiny regarding Donald Trump's involvement in geopolitical developments and the broader financial performance of the company. Investors are actively discussing the stock's volatility alongside speculation about potential future catalysts, while critics continue to highlight the company's lack of traditional fundamentals.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is facing intense debate from retail investors as recent selling activity by ARK Invest triggers concerns over the company's timeline for commercializing its 'Midnight' aircraft. While some participants are wary of the stock's sluggish technical progress compared to competitors, others are aggressively buying the dip, banking on long-term institutional backing and the anticipation of near-term catalysts like FAA milestones and defense partnerships.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang Holdings is currently seeing high volatility as investors weigh the company's recent expansion into international markets and progress toward commercial operations against ongoing sector-wide doubts regarding eVTOL commercialization timelines and regulatory hurdles. The community remains deeply divided, with some actively accumulating shares during price dips based on the company's first-mover status in the autonomous space, while others express frustration over delayed operational milestones and the impact of sector-wide analyst downgrades.

Nintendo Co., Ltd. engages in the development, manufacture, and sale of home entertainment products. Its entertainment products include portable and console game machines and software, trump cards and Karuta (Japanese-style playing cards), multinational consumer electronics, home console hardware such as Nintendo Wii, Nintendo DS, Nintendo 3DS, as well as software for handheld and home console gaming machines. The company was founded by Fusajiro Yamauchi on September 23, 1889 and is headquartered in Kyoto, Japan.

Nintendo Co. Ltd - ADR

Nintendo shares are facing increased volatility as investors react to the company delaying U.S. preorders for the Switch 2 due to uncertainty surrounding new trade tariffs. The community remains deeply divided, with many expressing frustration over the console's pricing strategy while others maintain high conviction in Nintendo's long-term growth and strong intellectual property.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investor sentiment builds ahead of an earnings release, fueled by excitement over recent patent extensions and anticipated approvals in the European market. Community discussion is focused on the stock's undervaluation, potential for a buyout, and the strong momentum leading into the company's financial update.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the transaction, the chief operating officer owned 4,517...

Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 4,517 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the sale, the chief operating officer...

AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales

Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Morgan Stanley upped their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the company an 'equal weight' rating in a report on Tuesday...

Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00

Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an 'overweight' rating in a research note on Tuesday...

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho

Mizuho increased their target price on Axsome Therapeutics from $228.00 to $310.00 and gave the company an 'outperform' rating in a report on Tuesday...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-one brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eighteen h...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism?

Equity

Bullish Sentiment

Traders are closely monitoring the $239 resistance level as the stock demonstrates technical momentum and consistent progress toward new all-time highs.

Speculation remains high regarding future partnership deals and the broader biotech acquisition climate, positioning the company as a potential industry leader.

AXSMAxsome Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AXSM News